Ameriprise
NGM

Ameriprise’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Ameriprise’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-116,751
Closed -$100K – 3994
2023
Q4 		$100K Buy
116,751
+35,340
+43% +$31K ﹤0.01% 3814
2023
Q3 		$87.1K Hold
81,411
– – ﹤0.01% 3809
2023
Q2 		$211K Sell
81,411
-2,201
-3% -$7.85K ﹤0.01% 3717
2023
Q1 		$341K Buy
83,612
+35,225
+73% +$163K ﹤0.01% 3572
2022
Q4 		$244K Buy
+48,387
New +$303K ﹤0.01% 3656

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise's NGM Position: Q1 2024 in Review

Ameriprise sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 116,751 shares — an estimated $100K sold.

Ameriprise first reported a position in NGM in Q4 2022 and held it in 5 quarters. The position peaked at $341K in Q1 2023. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Ameriprise reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Ameriprise sold 116,751 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $100K.
  • Ameriprise first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 5 quarters.
  • Ameriprise's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $341K in Q1 2023.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Ameriprise's 13F filing for Q1 2024, filed 15 May 2024.